|
|
Volumn 363, Issue 20, 2010, Pages 1966-1968
|
|
Sipuleucel-T immunotherapy for castration-resistant prostate cancer [1]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
GLUCOCORTICOID;
PREDNISONE;
PROVENGE;
ANTINEOPLASTIC AGENT;
CANCER VACCINE;
SIPULEUCEL-T;
TAXOID;
TISSUE EXTRACT;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CANCER SURVIVAL;
CASTRATION;
CASTRATION RESISTANT PROSTATE CANCER;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
LETTER;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
COST BENEFIT ANALYSIS;
DISEASE COURSE;
ECONOMICS;
IMMUNOTHERAPY;
MALE;
MORTALITY;
MULTIMODALITY CANCER THERAPY;
NOTE;
PROSTATE TUMOR;
DRUG ANTAGONISM;
ANTINEOPLASTIC ACTIVITY;
DRUG COST;
DRUG EFFICACY;
PATIENT CARE;
ANTINEOPLASTIC AGENTS;
CANCER VACCINES;
COMBINED MODALITY THERAPY;
COST-BENEFIT ANALYSIS;
DISEASE PROGRESSION;
HUMANS;
IMMUNOTHERAPY;
MALE;
PROSTATIC NEOPLASMS;
TAXOIDS;
TISSUE EXTRACTS;
GLUCOCORTICOIDS;
|
|
EID: 78149477335
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1009982 Document Type: Letter |
|
Times cited : (66)
|
|
References (5)
|
